Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection

by Medical Finance
in Coronavirus
Study: High prevalence of olfactory disorders 18 months after contracting COVID-19. Image Credit: Nenad Cavoski/Shutterstock
9
SHARES
105
VIEWS
Share on FacebookShare on Twitter

To date, 351 million individuals have been infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the coronavirus disease-2019 (COVID-19) pandemic. SARS-CoV-2, which belongs to the family Coronaviridae, has been characterized to be highly contagious and virulent.


Study: High prevalence of olfactory disorders 18 months after contracting COVID-19. Image Credit: Nenad Cavoski/ShutterstockStudy: High prevalence of olfactory disorders 18 months after contracting COVID-19. Image Credit: Nenad Cavoski/Shutterstock


Background


One of the common symptoms related to COVID-19 is olfactory dysfunction (OD). OD can be described as the inability to smell (anosmia), partially smell (hyposmia) during sniffing, or taste while eating. According to some previous reports, 50% of COVID-19 patients suffered from anosmia and 20% from hyposmia.


Additionally, a few COVID-19 patients also experienced parosmia. Scientists have reported that OD is connected with other health issues such as depression and weight gain. One of the important questions that have been raised is whether OD, after COVID-19 infection, is a transient or persistent problem.


Earlier research has indicated that OD could persist beyond seven months. One of the limitations of these studies is that it depends on the data provided by the participants. Other limitations include employing candidates with pre-existing OD and lacking a control group. In a new study published on the medRxiv* preprint server, scientists focused on determining the prevalence of OD eighteen months after COVID-19 infection. 


A new study


The study cohort in the current study consisted of participants from the ongoing community study that included healthcare workers from the Danderyd Hospital, Stockholm. All the participants were tested for SARS-CoV-2 IgG antibodies every four months since the pandemic began in Sweden.


Scientists identified a total of 320 healthcare workers with SARS-CoV-2 IgG antibodies. Among this group, ninety-eight individuals volunteered, whose average age was forty-seven, with a history of COVID-19 infection, to provide samples to researchers. All the ninety-eight participants experienced mild COVID-19 symptoms. To reduce the possibility of obtaining biased results, all individuals were invited, among which forty-one individuals were identified to have suffered from OD after COVID-19 infection. The mean age of these participants was 50 years. 


Olfactory functions were evaluated using the Sniffin’ Sticks method. The threshold, discrimination, and identification (TDI) scores were recorded, which provided insights into individuals’ olfactory function. A TDI score of ≥30.75 indicated normosmia, scores between 16.25 and 30.5 represented hyposmia, and scores ≤16.0 indicated anosmia.


Researchers evaluated gustatory performance using a whole-mouth spray test of five taste qualities. In this investigation, a score of ≤3 represented hypogeusia, and a score of 4 determined parosmia. Nasal problems and other associated problems were determined using the SNOT22 questionnaire.


Main results


Scientists reported the prevalence of olfactory loss after one and half years of contracting COVID-19 infection. This study cohort consisted of 4% of individuals with anosmia and 33% with hyposmia. 20% of individuals were marginally below the hyposmia cut-off value.


SNOT22 test confirmed that individuals with COVID-19 infection experienced more nasal discomfort than the control group. Gustatory testing also revealed that 3% of the COVID-19 patients experienced hypogeusia; however, no prevalence of hypogeusia was found in the control group. Interestingly, the overlap between OD and parosmia in the study cohort was small.


Conclusion


The authors reported the prevalence of smell and taste disorders, among a third (65%) of all SARS-CoV-2 IgG positive individuals, eighteen months after recovering from COVID-19 infection. They observed that 49% of individuals in this study cohort experienced parosmia. The current study indicated that these dysfunctions are persistent and may even be permanent in many COVID-19 recovered individuals. 


*Important notice


medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

Booster vaccines found to augment T-cell responses to SARS-CoV-2 Omicron

by Medical Finance
May 20, 2022
0

In a recent study published in the latest issue of the journal Cell, a team of researchers evaluated T-cell reactivity to...

Study: Hospitalisation for COVID-19 predicts long-lasting cerebrovascular impairment: A prospective observational cohort study​​​​​​​. Image Credit: SvedOliver / Shutterstock

Cerebrovascular impairment persists months after severe acute COVID-19, UK study

by Medical Finance
May 20, 2022
0

Researchers in the United Kingdom have conducted an observational cohort study on hospitalized patients and have found that the degree...

Study: COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism. Image Credit: sruilk/Shutterstock

Study investigates if prior SARS-CoV-2 infection increases sensitivity to toxin that induces parkinsonism

by Medical Finance
May 20, 2022
0

Viral infections have been implicated in precipitating neurological sequelae, including symptoms of parkinsonism. Mechanisms of viral encephalopathies proposed include...

Study: Innate immunity: the first line of defense against SARS-CoV-2. Image Credit: Kateryna Kon/Shutterstock

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

by Medical Finance
May 20, 2022
0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen of coronavirus disease 2019 (COVID-19), which has caused...

Study: The Evolution of the COVID-19 Pandemic Through the Lens of Google Searches. Image Credit: Olga Rolenko/Shutterstock

Google search data could predict new COVID-19 cases

by Medical Finance
May 20, 2022
0

In a recent study posted to Research Square*, researchers showed that Google search data could be utilized for monitoring the...

Study: Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. Image Credit: siam.pukkato/Shutterstock

Evaluating safety of three doses of messenger RNA-based COVID-19 vaccines

by Medical Finance
May 20, 2022
0

In a recent study published in JAMA Network Open, researchers evaluated the safety profile and adverse events associated with coronavirus disease...

Next Post
Study: Social Distancing Causally Impacts The Spread of SARS-CoV-2: A U.S. Nationwide Event Study. Image Credit: oatawa/Shutterstock

Causal impact of spontaneous relaxation of social distancing practices on spread of SARS-CoV-2 in US

Study: T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern. Image Credit: natatravel/Shutterstock

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022. Image Credit: Rido/Shutterstock
    COVID-19 booster or additional primary vaccination dose against SARS-CoV-2 Omicron in nursing home occupants
  • Study: Correlation between post-vaccination titres of combined IgG, IgA, and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK). Image Credit: Studio Romantic/Shutterstock
    Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply